IL3RA/CD123 Antibody #57481
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 70 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human IL3RA/CD123 protein. Antibodies are purified by peptide affinity chromatography.
Background
IL3RA/CD123 is the alpha subunit of an IL-3 receptor that also contains the common beta chain (βc) shared with receptors for other cytokines. IL3RA/CD123 alone binds to IL-3 with high specificity but low affinity and it does not transduce intracellular signaling, while βc alone does not bind to IL-3 appreciably. Together, IL3RA/CD123 and βc form the functional high-affinity receptor for IL-3. IL3RA/CD123 is mainly expressed on the hematopoietic progenitor cells, primarily the granulocytic and monocytic linages (1,2). IL3RA/CD123 is highly expressed on leukemic stem cells in the majority of AML (acute myeloid leukemia) patients and is correlated with poor prognosis. In addition, overexpression of IL3RA/CD123 has also been reported for other hematopoietic malignancies (3-5). It is considered as a valuable therapeutic target for these malignancies (6-8).
- Miyajima, A. (1992) Int J Cell Cloning 10, 126-34.
- Goodall, G.J. et al. (1993) Growth Factors 8, 87-97.
- Muñoz, L. et al. (2001) Haematologica 86, 1261-9.
- Testa, U. et al. (2002) Blood 100, 2980-8.
- Testa, U. et al. (2004) Leukemia 18, 219-26.
- Liu, K. et al. (2015) Life Sci 122, 59-64.
- Pemmaraju, N. (2017) Curr Hematol Malig Rep 12, 510-12.
- Cummins, K.D. and Gill, S. (2018) Leuk Lymphoma 59, 1539-53.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.